



Request for corporate support DCCG

Content

- 1: General information Dutch Colorectal Cancer Group**
- 2: Categories of sponsorship**
- 3: Sponsor benefits**
- 4: Sponsorship booking form**

1. General Information

Dutch Colorectal Cancer Group (DCCG)

The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology, radiotherapy, medical oncology, genetics, pathology, radiology, and gastroenterology). The primary goal of the DCCG is to initiate clinical scientific research and thereby to promote the quality of diagnosis and treatment of patients with colorectal cancer.

In the Netherlands an excellent infrastructure exists for the performance of multicentre clinical studies in patients with colorectal cancer. Examples of DCCG initiated clinical trials are the TME and CAIRO studies. The success of these studies is largely due to the collaboration between the relevant disciplines, such as surgery, radiotherapy, medical oncology, and pathology, as well as the support from data centers such as the regional trial offices of the Comprehensive Cancer Centers. This allows the conduct of large randomized studies with objectives that are relevant to clinical practice in the Netherlands and abroad.

Many of the DCCG initiated studies have been presented at international conferences and have been published in peer reviewed high ranked journals.

The scientific clinical research of the DCCG is taken into consideration for the development of guidelines for GI cancer in the Netherlands and a member of the national committee on guidelines for GI cancer is represented in the DCCG board.

New developments of the DCCG and their scientific clinical studies are communicated by newsletters that appear on a regular basis, as well as on the DCCG website (www.DCCG.nl) as during the annual DCCG conference.

The annual DCCG conference takes place at the end of the year and is intended to update the Dutch healthcare professionals involved in the treatment of colorectal cancer on the developments within this scientific area. Attendees will be updated on developments in colorectal cancer and ongoing and planned DCCG trials are being discussed. Dutch healthcare professionals are invited to submit abstracts / posters to be presented at this annual meeting that usually attracts between 150 – 200 attendees.

On a European / international level the DCCG has initiated the European Multidisciplinary Colorectal Cancer Congress (EMCCC) which takes place every 2 years and attracts attendees of all the medical disciplines involved in the treatment of colorectal cancer from various different countries.

The purpose of the EMCCC conference is to improve the quality of prevention, diagnosis, treatment and follow-up of patients with colorectal cancer by bringing all the relevant disciplines together.

Board of Dutch Colorectal Cancer Group

Prof. dr. C.J.A. Punt, Chairman - **Medical Oncology**

Prof. dr.P.J. Tanis, Secretary - **Surgical Oncology**

Prof. Dr. G. Meijer, **Pathology**

Prof. dr. R.G.H. Beets – Tan, **Radiology**

Prof. dr. N. Hoogerbrugge – van der Linden, **Clinical Genetics**

Prof. dr. J.Buijsen, **Radiotherapy**

Secretariat

Department of Medical Oncology

Academic Medical Center, University of Amsterdam

PO Box 22660

1100 DD Amsterdam

The Netherlands

Phone: +31 20 5665955

E-mail: secr-onco@amc.uva.nl

Management

Mw. F. Barbieri, MA

E-mail: feliciabarbieri@gmail.com

Phone: +31 (0)646357911

Completed and ongoing DCCG studies

COMPLETED, ONGOING and PLANNED STUDIES:

1. TME study - randomized phase III study evaluating the role of neoadjuvant radiotherapy with TME surgery in rectal cancer
2. CAIRO - randomized phase III study of sequential versus combination chemotherapy in metastatic colorectal cancer
3. CAIRO2 - randomized phase III study of chemotherapy plus bevacizumab with or without cetuximab in metastatic colorectal cancer
4. CAIRO3 - randomized phase III study of maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer
5. CARTS – phase II study of chemoradiation for distal rectal cancer followed by organ-sparing transanal endoscopic microsurgery
6. RAX/REX - phase II study of neoadjuvant chemotherapy plus bevacizumab in locally advanced rectal cancer
7. SILENT – randomized phase II study on the effect of neoadjuvant systemic therapy on synchronous metastatic growth after resection of the primary tumour in colorectal cancer
8. M1 – phase II study on a staged approach in synchronous metastatic rectal cancer
9. HEPATICA - randomized phase III study of adjuvant chemotherapy with or without bevacizumab after radical metastasectomy for colorectal cancer liver metastases
10. PROCTOR/SCRIPT - randomized phase III study of adjuvant capecitabine versus observation in stage II-III rectal cancer
11. CRITICS - randomized phase III study of postoperative chemotherapy versus chemoradiotherapy after neoadjuvant chemotherapy and surgery for gastric cancer
12. CAIRO4 - randomized phase III study of resection versus no resection of the primary tumour in synchronous metastatic colon cancer with few or absent symptoms of the primary tumour.
13. CAIRO5 - randomized phase II study of different neoadjuvant strategies in initially irresectable colorectal cancer liver metastases
14. RAPIDO - randomized phase III study on short course radiotherapy with preoperative chemotherapy in primary high rectal cancer with high risk for recurrence compared to standard neoadjuvant chemoradiotherapy

2. Categories of sponsorship

level	Commitment	Support per year	Benefits
Corporate Platinum	3 years	€ 10.000,00	<ul style="list-style-type: none"> • 1 hour meeting with the DCCG board in conjunction with the biennial EMCCC-meeting • Recognition on the website of the DCCG • Company presentation with a link to the company website. • Access to DCCG approved slide sets • Periodical newsletter sent to all DCCG members with acknowledgement of support & Sponsor logo on main page of the newsletter. • The opportunity to implement scientific approved information of max 300 words with link to company website in the DCCG newsletter. • 20 % rebate on cost of a satellite symposium during the EMCCC conference and on costs of exhibition
Corporate Gold	3 years	€ 7.500,00	<ul style="list-style-type: none"> • Recognition on the website of the DCCG • Company presentation with a link to the company website. • Access to DCCG approved slide sets • Periodical newsletter sent to all DCCG members with acknowledgement of support & Sponsor logo on main page of the newsletter. • The opportunity to implement scientific approved information of max 300 words in the DCCG newsletter • 10 % rebate on cost of a satellite symposium during the EMCCC conference and on costs of exhibition
Corporate Silver	2 years	€ 5.000,00	<ul style="list-style-type: none"> • Recognition on the website of the DCCG • Access to DCCG approved slide sets • Periodical newsletter sent to all DCCG members with acknowledgement of support & Sponsor logo on main page of the newsletter. • 10 % rebate on cost of a satellite symposium during the EMCCC conference and on costs of exhibition
Corporate Bronze	2 years	€ 3.000,00	<ul style="list-style-type: none"> • Recognition on the website of the DCCG • Access to DCCG approved slide sets • Periodical newsletter sent to all DCCG members with acknowledgement of support & Sponsor logo on main page of the newsletter.

3. Sponsor Benefits

Why become a Sponsor of DCCG?

DCCG gives access to Dutch Healthcare professionals involved in the diagnosis and treatment of colorectal cancer. Furthermore the majority of clinical trials in the Netherlands in colorectal cancer are initiated by the DCCG.

Who will you reach?

DCCG draws its highly regarded members from the entire spectrum of gastrointestinal oncology. Specialists and researchers in the field of colorectal cancer with interest in: Medical Oncology, Surgical Oncology, Radio Oncology, Pathology, Gastroenterology, Imaging, Radiology, Basic Science and Genetics. Other healthcare providers who are significant involved in oncology patient care, in both academia and community-based setting make up the core membership. The more than 300 members prescribe and/or influence the use of systemic drugs, hormones, and biologic agents in the treatment of colorectal cancer.

Congresses & Courses

The Dutch Colorectal Cancer Group is highly committed to promoting education in colorectal cancer. By providing the European Gastrointestinal oncology community with a wide range of educational opportunities and initiatives, DCCG contributes to the advancement of knowledge and expertise in colorectal cancer and the clinical management of cancer patients:

- DCCG's biennial EMCCC congress provides GI-oncologists / specialists with the most expansive and interconnectivity educational platform of Europe,
- DCCG's annual meeting provides GI-oncologists / specialists with the most expansive and interconnectivity educational platform of the Netherlands.

All these activities are open for industry sponsorship. Please contact our manager for more information. DCCG has many other sponsor opportunities to bring your company into contact with DCCG members. We would be happy to discuss these opportunities with you. DCCG is also very much interested in your own ideas to effectively communicate with the members.

4. Sponsorship Support Booking Form

Name of Company _____

Contact Name _____

Job Title _____

Address _____

Post/Zip Code _____

Country _____

Telephone _____

E-mail _____

Website: _____

We hereby apply to be a:

DCCG corporate sponsor	Rates in Euros	✓
PLATINUM sponsor	€ 10,000	
GOLD sponsor	€ 7,500	
SIIVER sponsor	€ 5,000	
BRONZE sponsor	€ 3,000	

- Please call me to discuss our corporate support opportunities
- Please send me a corporate support contract
- Please contact me, I'm interested in sponsoring DCCG conference (annual meeting, EMCCC conference and / or educational courses
- Please contact me to discuss other corporate support opportunities

SIGNATURE: _____ DATE: _____

